Respiratory therapies company Cornerstone Therapeutics has named a Quintiles executive to become the company’s new chief financial officer.
Vincent Morgus has been senior vice president, corporate development at Quintiles since 2003. His new job at Cary, North Carolina-based Cornerstone (NASDAQ:CRTX) started on Feb. 1.
Morgus is a veteran of Quintiles. He started at the clinical research organization in 1994 and progressed through a variety of financial management positions in the company. Before working at Quintiles, Morgus worked at Q+E Software and DaVinci Systems Corp. He started his career as an auditor for Arthur Andersen.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Morgus replaces former CFO David Price, who left the company last June.
Cornerstone specializes in respiratory drugs. Its top-selling product is Curosurf, a treatment for respiratory distress syndrome in infants that generated $23.7 million in sales through the nine months ending Sept. 30, 2010.
